FDG gamma camera PET equipped with one inch crystal and XCT

2006 ◽  
Vol 45 (04) ◽  
pp. 163-170
Author(s):  
A. Khorsand ◽  
S. Graf ◽  
G. Dobrozemsky ◽  
S. Oezer ◽  
K. Kletter ◽  
...  
Keyword(s):  
Clinical Studies ◽  
Gamma Camera ◽  
Single Photon ◽  
Photon Emission ◽  
Regional Analysis ◽  
Correlation Coefficients ◽  
Emission Tomography ◽  
Metabolic Imaging ◽  
99Mtc Tetrofosmin ◽  
Dedicated Pet

SummaryMetabolic imaging with 2-[fluorine-18]-fluoro- 2-deoxy-D-glucose (FDG) is actually considered as the best method to detect and quantitatively assess myocardial tissue viability. The aim of this study was to investigate the accuracy of FDG gamma camera positron emission tomography (GCPET) imaging equipped with one inch NaI crystals in comparison to FDG dedicated PET (dPET) imaging as a „gold standard“ in phantom and clinical studies. Patients, methods: Nineteen patients with coronary artery disease (CAD) underwent both imaging modalities. Phantom and clinical GCPET imaging were performed with a dual-headed, coincidence based gamma camera equipped with 1 inch thick NaI crystals and an x-ray tube (XCT) for attenuation correction (AC), as well as with a dedicated PET scanner with AC. 99mTc tetrofosmin single-photon emission tomography (SPET) studies were performed for assessment of myocardial perfusion, with AC. Results: Phantom studies showed a significant relation in segmental activity between FDG imaging with AC using GCPET and dPET (r = 0.91, p <0.001). In clinical studies with AC correlation coefficients of mean segmental FDG uptake and regional defect size were r = 0.87 (p <0.0001) and r = 0.83 (p <0.0001), respectively. In regional analysis close agreement was even found in the most attenuated regions of the heart if AC was used in GCPET imaging. The overall agreement for detection of viable myocardium was 81% between FDG-dPET (AC) and FDG-GCPET (AC) and 74% between FDG-dPET (AC) and FDG-GCPET (NC). Conclusion: This study suggests that the assessment of myocardial metabolism by means of FDG is feasible with a coincidence based gamma camera equipped with 1 inch thick NaI crystals if AC is performed. The results reveal a close concordance and agreement between FDG-dPET (AC) and FDG-GCPET (AC) as compared to FDG-GCPET (NC).

scholarly journals Nuclear Imaging of Glucose Metabolism: Beyond 18F-FDG

2019 ◽  
Vol 2019 ◽  
pp. 1-12 ◽  
Author(s):  
Han Feng ◽  
Xiaobo Wang ◽  
Jian Chen ◽  
Jing Cui ◽  
Tang Gao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Tumor Imaging ◽  
Single Photon ◽  
Photon Emission ◽  
Nuclear Imaging ◽  
Emission Tomography ◽  
Metabolic Imaging ◽  
Emission Computed Tomography ◽  
Positron Emission

Glucose homeostasis plays a key role in numerous fundamental aspects of life, and its dysregulation is associated with many important diseases such as cancer. The atypical glucose metabolic phenomenon, known as the Warburg effect, has been recognized as a hallmark of cancer and serves as a promising target for tumor specific imaging. At present, 2-deoxy-2-[18F]fluoro-glucose (18F-FDG)-based positron emission tomography/computed tomography (PET/CT) represented the state-of-the-art radionuclide imaging technique for this purpose. The powerful impact of 18F-FDG has prompted intensive research efforts into other glucose-based radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging. Currently, glucose and its analogues have been labeled with various radionuclides such as 99mTc, 111In, 18F, 68Ga, and 64Cu and have been successfully investigated for tumor metabolic imaging in many preclinical studies. Moreover, 99mTc-ECDG has advanced into its early clinical trials and brings a new era of tumor imaging beyond 18F-FDG. In this review, preclinical and early clinical development of glucose-based radiopharmaceuticals for tumor metabolic imaging will be summarized.

Clinical applications of single photon emission tomography in neuromedicine

2000 ◽  
Vol 39 (08) ◽  
pp. 218-231 ◽  
Author(s):  
F. Grünwald ◽  
T. Kuwert ◽  
K. Tatsch ◽  
O. Sabri ◽  
O. Benkert ◽  
...  
Keyword(s):  
Single Photon ◽  
Inflammatory Diseases ◽  
Photon Emission ◽  
Clinical Applications ◽  
Emission Tomography ◽  
Receptor Ligands ◽  
Single Photon Emission ◽  
The Central Nervous System ◽  
Dementing Disorders ◽  
Photon Emission Tomography

SummaryThis article gives in his second part a critical review of the clinical applications of SPECT with perfusion markers and receptor ligands in dementing disorders and psychosis. In addition this review discusses clinical applications of SPECT investigations with perfusion markers in inflammatory diseases of the central nervous system and in brain trauma.

Myocardial Metabolic Imaging in the Clinical Setting

2009 ◽  
Vol 5 (1) ◽  
pp. 15
Author(s):  
Nagara Tamaki ◽  
Yuji Kuge ◽  
Keiichiro Yoshinaga ◽  
◽  
◽  
...  
Keyword(s):  
Heart Failure ◽  
Fatty Acid ◽  
Clinical Setting ◽  
Photon Emission ◽  
Tca Cycle ◽  
Emission Tomography ◽  
Metabolic Imaging ◽  
Myocardial Uptake ◽  
Glucose Utilisation ◽  
Myocardial Metabolic Imaging

Glucose and free fatty acids are a major energy source in the myocardium. Metabolic imaging with single photon emission tomography (SPECT) and positron emission tomography (PET) have been widely used for the evaluation of the pathophysiology of coronary artery disease (CAD) and heart failure. 18F fluorodeoxyglucose (FDG) is a glucose analogue that is used to measure myocardial glucose utilisation. The myocardial uptake of a modified branched fatty acid, 15-(p-[iodine-123] iodophenyl)-3-(R,S) methylpentadecanoic acid (BMIPP), reflects the activation of fatty-acid metabolism by co-enzyme A (CoA) and indirectly reflects cellular adenosine triphosphate (ATP) production. The turnover rate of the tricarboxylic acid (TCA) cycle reflects the rate of overall myocardial oxidative metabolism. 11C acetate is readily metabolised to CO2 almost exclusively through the TCA cycle. These three major agents have been most commonly used for probing myocardial energy metabolism in vivo. Such metabolic imaging has been used for assessing myocardial viability on the basis of persistent glucose utilisation in ischaemic but viable myocardium. BMIPP and FDG have been identified for locating a recent history of myocardial ischaemia. Furthermore, metabolic imaging is promising for the assessment of the pathophysiology of heart failure and the treatment effect of various drugs, as well as mechanical treatments. In this article we will provide an overview of the application of myocardial metabolic imaging in a clinical setting.

Sign in / Sign up

Export Citation Format

Share Document